GO:0051583 dopamine uptake involved in synaptic transmission: Synaptic Reuptake Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0051583 describes the directed movement of dopamine into a presynaptic neuron or glial cell, a process central to terminating dopaminergic signaling.
• The dopamine transporter (DAT/SLC6A3) is the principal protein mediating dopamine reuptake from the synaptic cleft.
• Dopamine uptake is essential for regulating extracellular dopamine levels and preventing excessive receptor activation.
• Dysregulation of dopamine uptake is implicated in schizophrenia, cocaine sensitization, and ischemic stroke [1,4,8].
• The VMAT-DAT-dopamine regulatory system coordinates vesicular storage and reuptake, and is a target for neuroprotective strategies.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal dissection of dopamine uptake genes in vitro and in vivo.
Description
Dopamine is a catecholamine neurotransmitter that modulates motor control, reward, cognition, and emotion. Following its release into the synaptic cleft, dopamine must be rapidly cleared to terminate signaling and maintain homeostasis. GO:0051583, dopamine uptake involved in synaptic transmission, captures the directed movement of dopamine into a presynaptic neuron or glial cell, a process that is fundamental to dopaminergic neurotransmission. This term is distinct from vesicular packaging and receptor activation, focusing specifically on the reuptake step that shapes the amplitude and duration of dopamine signals. The dopamine transporter (DAT, encoded by SLC6A3) is the primary molecular mediator of this process, and its activity is a key determinant of dopaminergic tone. Dopamine uptake is not merely a clearance mechanism; it is a dynamic regulator of synaptic plasticity and network activity. Heterogeneity in dopamine neuron synaptic actions across the striatum underscores the importance of uptake in region-specific signaling. Moreover, the interplay between dopamine uptake and other neurotransmitter systems, such as purinergic cotransmission, highlights the integrative nature of this process. The extracellular space environment, including diffusion barriers and glial contributions, further modulates dopamine availability and reuptake efficiency. For researchers, GO:0051583 provides a precise ontological handle to study the molecular machinery, regulatory mechanisms, and pathological alterations of dopamine reuptake. It is a critical node in addiction, neurodegenerative disorders, and ischemic injury, making it a prime target for CRISPR-based functional genomics and therapeutic development [4,5,8].
dopamine uptake involved in synaptic transmission At A Glance
| GO ID | GO:0051583 |
|---|---|
| GO term | dopamine uptake involved in synaptic transmission |
| Ontology | biological_process |
| Synonym | dopamine import involved in synaptic transmission; dopamine reuptake involved in synaptic transmission |
| Major function | Directed movement of dopamine into a presynaptic neuron or glial cell, terminating synaptic signaling and recycling the neurotransmitter |
| Cellular location | Presynaptic plasma membrane, glial cell membrane |
| Key transporter | Dopamine transporter (DAT/SLC6A3) |
| Related process | Vesicular dopamine storage via VMAT2, dopamine synthesis, and receptor signaling |
| Disease relevance | Schizophrenia, cocaine sensitization, ischemic stroke, addiction |
What Is GO:0051583?
GO:0051583, dopamine uptake involved in synaptic transmission, is defined as the directed movement of dopamine into a presynaptic neuron or glial cell. In this context, dopamine is a catecholamine neurotransmitter and a metabolic precursor of noradrenaline and adrenaline. This process is synonymous with dopamine import and dopamine reuptake involved in synaptic transmission. It encompasses the transport of dopamine from the extracellular space back into cells, primarily via the dopamine transporter (DAT), thereby terminating synaptic signaling and recycling the neurotransmitter [1,8].
Why Is dopamine uptake involved in synaptic transmission Important in Cell Biology?
Dopamine uptake is a fundamental determinant of dopaminergic neurotransmission, controlling the spatial and temporal dynamics of dopamine in the synaptic cleft. By removing dopamine from the extracellular space, this process prevents receptor desensitization and maintains the fidelity of phasic and tonic signaling. Dysregulation of dopamine uptake is directly linked to neuropsychiatric disorders such as schizophrenia, where altered dopamine neuron synaptic actions across the striatum contribute to pathophysiology. In addiction, cocaine binds to DAT and inhibits dopamine reuptake, leading to elevated extracellular dopamine and sensitization. Furthermore, the VMAT-DAT-dopamine regulatory system is involved in neuroprotection against ischemic stroke, highlighting the clinical potential of targeting this pathway [5,8]. Understanding GO:0051583 is therefore essential for deciphering brain function and developing therapeutics for dopamine-related diseases.
• Regulates extracellular dopamine concentration and terminates synaptic transmission.
• Shapes phasic and tonic dopamine signaling critical for motor control, reward, and cognition.
• Dysfunction is implicated in schizophrenia and other psychiatric disorders.
• Cocaine and other psychostimulants inhibit DAT, causing dopamine accumulation and sensitization.
• The VMAT-DAT-dopamine system is a target for neuroprotection in ischemic stroke [5,8].
• Glial cells participate in dopamine uptake, influencing neurotransmitter clearance.
• Purinergic cotransmission can modulate dopamine release and reuptake.
• Genetic variation in SLC6A3 (DAT) is associated with altered dopamine uptake and disease risk.
• Dopamine uptake is a key node for CRISPR-based functional studies and drug discovery.
What Happens During dopamine uptake involved in synaptic transmission?
Dopamine release and extracellular accumulation
In simple terms: Dopamine is released from the presynaptic neuron into the space between neurons.
Dopamine is packaged into synaptic vesicles by VMAT2 and released into the synaptic cleft upon neuronal firing. Once in the extracellular space, dopamine can bind to postsynaptic and presynaptic receptors, but its action must be terminated by reuptake [1,5]. The extracellular environment, including diffusion barriers and glial cells, influences how far dopamine can spread before being cleared.
Recognition and binding by the dopamine transporter (DAT)
In simple terms: A specialized protein on the presynaptic membrane grabs dopamine from outside the cell.
The dopamine transporter (DAT, SLC6A3) is a sodium- and chloride-dependent transporter located on the presynaptic plasma membrane. It recognizes dopamine with high affinity and undergoes conformational changes to translocate the neurotransmitter into the cytoplasm. DAT is the primary molecular mediator of GO:0051583, and its expression levels and activity directly determine reuptake efficiency.
Translocation of dopamine into the presynaptic neuron
In simple terms: Dopamine is moved from outside to inside the neuron.
Upon binding, DAT couples the inward transport of dopamine to the electrochemical gradient of sodium and chloride ions. This secondary active transport mechanism moves dopamine against its concentration gradient into the presynaptic neuron. The process is rapid and ensures that extracellular dopamine levels are kept within a narrow physiological range.
Glial contribution to dopamine clearance
In simple terms: Support cells in the brain also help remove dopamine.
In addition to presynaptic neurons, glial cells can take up dopamine, contributing to neurotransmitter clearance. This glial uptake is particularly relevant in regions with high dopamine turnover and may involve transporters other than DAT. The interplay between neuronal and glial uptake shapes the overall dynamics of dopamine signaling.
Recycling and re-vesicularization
In simple terms: After being taken back up, dopamine can be reused or broken down.
Once inside the presynaptic neuron, dopamine can be re-packaged into synaptic vesicles by VMAT2 for future release, or it can be degraded by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT). The VMAT-DAT-dopamine regulatory system coordinates these processes to maintain dopamine homeostasis. This recycling is essential for sustained neurotransmission and is a target for neuroprotective strategies.
Key Genes Involved in GO:0051583 dopamine uptake involved in synaptic transmission
The following genes and proteins are central to dopamine uptake involved in synaptic transmission (GO:0051583), based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC6A3 (DAT) | Primary dopamine transporter mediating reuptake from the synaptic cleft | Target for cocaine, psychostimulants, and neuropsychiatric disorders [4,8] |
| SLC18A2 (VMAT2) | Vesicular monoamine transporter that packages dopamine into synaptic vesicles | Coordinates with DAT in the VMAT-DAT-dopamine regulatory system |
| DRD1 | Dopamine receptor D1, postsynaptic receptor that responds to extracellular dopamine | Modulates signaling downstream of uptake; relevant to schizophrenia |
| DRD2 | Dopamine receptor D2, presynaptic autoreceptor that regulates dopamine release | Feedback regulation of dopamine uptake and release |
| TH | Tyrosine hydroxylase, rate-limiting enzyme in dopamine synthesis | Determines dopamine availability for uptake |
| DDC | Dopa decarboxylase, converts L-DOPA to dopamine | Dopamine synthesis pathway |
| MAOA | Monoamine oxidase A, degrades dopamine after reuptake | Dopamine catabolism and homeostasis |
| MAOB | Monoamine oxidase B, degrades dopamine in glia | Glial contribution to dopamine clearance |
| COMT | Catechol-O-methyltransferase, degrades dopamine | Dopamine metabolism and prefrontal cortex function |
| SLC6A2 (NET) | Norepinephrine transporter, can transport dopamine in some regions | Contributes to dopamine clearance in prefrontal cortex |
| SLC6A4 (SERT) | Serotonin transporter, low affinity for dopamine | Potential minor role in dopamine uptake |
| GRM2 (mGluR2) | Metabotropic glutamate receptor 2, modulates dopamine release | Indirect regulation of dopamine uptake |
| GRIN1 (NMDA receptor subunit) | NMDA receptor subunit involved in cocaine-induced plasticity | Cocaine sensitization alters NMDA receptor expression |
| GRIN2A | NMDA receptor subunit 2A | Cocaine-induced changes in NMDA receptor subunits |
| GRIN2B | NMDA receptor subunit 2B | Cocaine-induced changes in NMDA receptor subunits |
| P2RX7 | Purinergic receptor involved in cotransmission | Modulates dopamine release and uptake |
| ADORA2A | Adenosine A2A receptor, interacts with dopamine signaling | Regulates dopamine uptake and release |
| SLC1A1 (EAAT3) | Glutamate transporter, may influence dopamine via glutamate | Indirect modulation of dopamine uptake |
How Is dopamine uptake involved in synaptic transmission Regulated?
Dopamine uptake via DAT is tightly regulated at multiple levels. Transcriptional regulation of SLC6A3 controls transporter density, while post-translational modifications such as phosphorylation and ubiquitination modulate DAT surface expression and activity. Presynaptic D2 autoreceptors provide feedback inhibition of dopamine release and can also influence DAT function. Cocaine and other psychostimulants directly bind to DAT and inhibit reuptake, leading to elevated extracellular dopamine and neuroadaptive changes, including altered NMDA receptor subunit expression [4,6]. The VMAT-DAT-dopamine regulatory system integrates vesicular storage and reuptake, and its disruption is linked to ischemic stroke pathology. Additionally, purinergic cotransmission and adenosine receptor signaling can modulate dopamine uptake indirectly.
dopamine uptake involved in synaptic transmission and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC6A3 (DAT) | Schizophrenia, cocaine addiction, ADHD | DAT knockout mice, point-mutation knock-in for cocaine insensitivity [4,8] |
| SLC18A2 (VMAT2) | Ischemic stroke, Parkinson's disease | VMAT2 conditional knockout, overexpression for neuroprotection |
| GRIN1/GRIN2A/GRIN2B | Cocaine sensitization, schizophrenia | NMDA receptor subunit knockout and point-mutation models |
| DRD2 | Schizophrenia, addiction | D2 receptor knockout and conditional knock-in |
| P2RX7 | Purinergic cotransmission, neuroinflammation | P2X7 knockout and overexpression |
Schizophrenia and dopaminergic dysfunction
Schizophrenia is associated with altered dopamine neuron synaptic actions across the striatum, where heterogeneity in dopamine release and uptake contributes to positive and negative symptoms. Dysregulation of dopamine uptake can lead to excessive or insufficient dopaminergic signaling in specific striatal subregions, and DAT availability has been studied as a biomarker. The dopamine transporter is a key node linking genetic risk factors to functional dopamine abnormalities in schizophrenia.
Cocaine addiction and sensitization
Cocaine binds to DAT and inhibits dopamine reuptake, causing a rapid increase in extracellular dopamine that underlies its reinforcing effects. Repeated cocaine exposure leads to sensitization, involving cortical mechanisms and changes in NMDA receptor subunit expression [4,6]. These neuroadaptations alter dopamine uptake dynamics and contribute to addiction-related behaviors [4,6].
Ischemic stroke and neuroprotection
The VMAT-DAT-dopamine regulatory system is involved in the protective effect of 3-n-butylphthalide against ischemic stroke. Dysregulation of dopamine uptake during ischemia can exacerbate excitotoxicity and oxidative stress, and targeting DAT or VMAT2 may offer neuroprotective strategies. The dopamine transporter has been proposed as a new target for ischemic stroke therapy.
Other neurological and psychiatric conditions
Alterations in dopamine uptake have been implicated in mood disorders, attention-deficit hyperactivity disorder (ADHD), and Parkinson's disease, although the exact mechanisms vary [1,8]. The complementary control of approach and avoidance behaviors by dopamine and serotonin neurotransmissions highlights the broader behavioral relevance of dopamine clearance. Continued research into GO:0051583 may reveal additional disease connections.
From dopamine uptake involved in synaptic transmission-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of DAT abolish dopamine reuptake? | DAT knockout cell lines and mice |
| How do point mutations in SLC6A3 affect transporter function? | CRISPR point-mutation knock-in in neuroblastoma cells |
| Can a tagged DAT be used to track localization? | Knock-in of fluorescent or epitope tags at the SLC6A3 locus |
| Does overexpression of VMAT2 enhance dopamine storage? | VMAT2 overexpression in dopaminergic neurons |
| What is the role of glial cells in dopamine clearance? | Glial-specific knockout of candidate transporters |
| How does cocaine alter NMDA receptor subunit expression? | Cocaine-treated knockout and point-mutation models |
How to Study the dopamine uptake involved in synaptic transmission Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Fast-scan cyclic voltammetry | Real-time dopamine release and uptake kinetics | Brain slices, in vivo recordings [1,4] |
| Radioligand uptake assay | Transporter activity and kinetics | Cell lines, synaptosomes |
| Immunoblotting | Protein expression levels of DAT, VMAT2, etc. | CRISPR-edited cell lysates |
| Immunohistochemistry | Spatial distribution of transporters | Brain tissue sections |
| RNA-seq | Transcriptional changes in dopamine pathway genes | Knockout and overexpression models |
| Proteomics | Protein abundance and post-translational modifications | Drug-treated and edited cells |
| Live-cell imaging | Transporter trafficking and membrane localization | Tagged knock-in cells |
| Behavioral assays | Locomotor activity, reward, sensitization | DAT mutant mice |
Fast-scan cyclic voltammetry (FSCV)
FSCV is the gold-standard method for measuring real-time dopamine release and uptake in brain slices and in vivo. It detects oxidation currents of dopamine with subsecond temporal resolution, allowing researchers to quantify uptake rates and the effects of DAT inhibitors [1,4]. This method is essential for validating CRISPR models of dopamine uptake genes.
Radioligand binding and uptake assays
Radiolabeled dopamine or DAT-specific ligands (e.g., [3H]dopamine, [125I]RTI-55) are used to measure transporter density and uptake kinetics in cell lines and synaptosomes. These assays can be applied to CRISPR-edited cells to assess the functional impact of specific mutations.
Immunohistochemistry and imaging
Antibodies against DAT, VMAT2, and other proteins allow visualization of transporter localization in brain tissue and cultured cells. Fluorescent tagging via CRISPR knock-in enables live-cell imaging of transporter trafficking and membrane dynamics.
Transcriptomics and proteomics
RNA-seq and mass spectrometry can quantify expression changes in dopamine uptake-related genes following genetic or pharmacological perturbations. These approaches are useful for identifying compensatory mechanisms and off-target effects in CRISPR models [5,6].
How CRISPR Can Be Used to Study GO:0051583 dopamine uptake involved in synaptic transmission
Knockout
CRISPR knockout of SLC6A3 (DAT) in cell lines or mice abolishes dopamine reuptake, leading to elevated extracellular dopamine and altered behaviors. Knockout models are used to study the consequences of loss of function and to validate drug targets. Conditional knockout allows tissue-specific ablation to avoid developmental compensation.
Point Mutation
Point mutations in SLC6A3 can mimic naturally occurring variants or disrupt key residues for substrate binding or cocaine sensitivity. CRISPR point-mutation knock-in generates isogenic cell lines to dissect the molecular basis of transporter function and drug interactions. Such models are valuable for precision medicine approaches.
Knock-in
Knock-in of reporter tags (e.g., GFP, HA) at the endogenous SLC6A3 locus enables real-time tracking of DAT expression and localization without overexpression artifacts. Knock-in of disease-associated mutations provides physiologically relevant models for studying dopamine uptake dysfunction. This approach is also used to introduce Cre recombinase for lineage tracing.
Overexpression
Overexpression of DAT or VMAT2 via CRISPR activation or transgenic insertion can enhance dopamine uptake and storage, respectively. These models are used to test whether increased clearance is protective in conditions of dopamine excess, such as ischemia or addiction. Overexpression in cell lines facilitates biochemical studies of transporter kinetics.
How EDITGENE Supports dopamine uptake involved in synaptic transmission Research
Researchers studying dopamine uptake involved in synaptic transmission-related genes often need to determine whether a candidate gene is causally involved in transporter function, drug response, or disease pathology. EDITGENE provides a comprehensive suite of CRISPR services to generate precisely engineered cell and animal models, enabling rigorous functional validation of genes such as SLC6A3, SLC18A2, and their regulators.
Contact EDITGENE today to design your custom CRISPR model for dopamine uptake involved in synaptic transmission research.
Frequently Asked Questions About dopamine uptake involved in synaptic transmission
What is GO:0051583?
GO:0051583 is the Gene Ontology term for dopamine uptake involved in synaptic transmission, defined as the directed movement of dopamine into a presynaptic neuron or glial cell.
What genes are involved in dopamine uptake involved in synaptic transmission?
Key genes include SLC6A3 (DAT), SLC18A2 (VMAT2), DRD1, DRD2, TH, DDC, MAOA, MAOB, and COMT, among others [1,5,8].
How is dopamine reuptake regulated?
Dopamine reuptake is regulated by DAT expression, phosphorylation, presynaptic autoreceptors, and interactions with other neurotransmitter systems such as purinergic signaling [2,8].
What diseases are associated with impaired dopamine uptake?
Impaired dopamine uptake is associated with schizophrenia, cocaine addiction, ischemic stroke, ADHD, and Parkinson's disease [1,4,5,8].
What is the role of the dopamine transporter (DAT)?
DAT (SLC6A3) is the primary protein that mediates dopamine reuptake from the synaptic cleft into presynaptic neurons, terminating dopaminergic signaling.
How can CRISPR be used to study dopamine uptake?
CRISPR can create knockout, point-mutation, knock-in, and overexpression models of genes like SLC6A3 to dissect their roles in dopamine uptake and disease.
What methods measure dopamine uptake?
Fast-scan cyclic voltammetry, radioligand uptake assays, and amperometry are commonly used to measure dopamine uptake in real time [1,4].
Is dopamine uptake involved in cocaine addiction?
Yes, cocaine inhibits DAT, blocking dopamine reuptake and leading to elevated extracellular dopamine, which underlies its addictive properties.
What is the VMAT-DAT-dopamine regulatory system?
It is a coordinated system where VMAT2 packages dopamine into vesicles and DAT clears extracellular dopamine, maintaining dopamine homeostasis and neuroprotection.
How does glial dopamine uptake differ from neuronal uptake?
Glial cells can take up dopamine via transporters such as NET and possibly other mechanisms, contributing to clearance especially in regions with high dopamine turnover.
Conclusion
GO:0051583, dopamine uptake involved in synaptic transmission, is a fundamental biological process that controls the duration and strength of dopaminergic signaling. The dopamine transporter DAT is the central mediator, and its dysfunction is linked to major neuropsychiatric and neurological disorders. Understanding the molecular mechanisms, regulation, and disease relevance of dopamine uptake is essential for developing targeted therapies. CRISPR-based models offer powerful tools to dissect these mechanisms with unprecedented precision, and EDITGENE provides the expertise and services to accelerate such research.
References
- 1. Chuhma N et al.. 2017. Heterogeneity in Dopamine Neuron Synaptic Actions Across the Striatum and Its Relevance for Schizophrenia.. Biol Psychiatry 81(1):43-51 PMID: 27692238
- 2. Burnstock G. 2009. Purinergic cotransmission.. Exp Physiol 94(1):20-4 PMID: 18723580
- 3. Nicholson C. 1988. Issues involved in the transmission of chemical signals through the brain extracellular space.. Acta Morphol Neerl Scand 26(2-3):69-80 PMID: 2908164
- 4. Steketee JD. 2005. Cortical mechanisms of cocaine sensitization.. Crit Rev Neurobiol 17(2):69-86 PMID: 16808728
- 5. Zhou XT et al.. 2026. VMAT-DAT-Dopamine Regulatory System Involved in the Protective Effect of 3-n-Butylphthalide Against Ischemic Stroke.. CNS Neurosci Ther 32(8):e71094 PMID: 42613797
- 6. Smaga I et al.. 2019. Cocaine-induced Changes in the Expression of NMDA Receptor Subunits.. Curr Neuropharmacol 17(11):1039-1055 PMID: 31204625
- 7. Gauthier L et al.. 2025. Dopamine and serotonin neurotransmissions exert complementary control over primate approach and avoidance.. Transl Psychiatry 16(1):27 PMID: 41461630
- 8. Cheng YQ et al.. 2024. The Dopamine Transporter Is a New Target for Ischemic Stroke.. CNS Neurosci Ther 30(10):e70092 PMID: 39467829
